Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
Erik S. Knudsen, Vishnu Kumarasamy, Ram Nambiar, et al.
Cell Reports (2022) Vol. 38, Iss. 9, pp. 110448-110448
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Squamous cell lung cancer: Current landscape and future therapeutic options
Sally C. M. Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Cancer Cell (2022) Vol. 40, Iss. 11, pp. 1279-1293
Open Access | Times Cited: 98
Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
Shazia Sofi, Umar Mehraj, Hina Qayoom, et al.
Medical Oncology (2022) Vol. 39, Iss. 9
Open Access | Times Cited: 90
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
Mansi Arora, Justin Moser, Timothy E. Hoffman, et al.
Cell (2023) Vol. 186, Iss. 12, pp. 2628-2643.e21
Open Access | Times Cited: 72
Protein conformational ensembles in function: roles and mechanisms
Ruth Nussinov, Yonglan Liu, Wengang Zhang, et al.
RSC Chemical Biology (2023) Vol. 4, Iss. 11, pp. 850-864
Open Access | Times Cited: 36
AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent/p53-dependent pathway
Bou‐Yue Peng, Abhinay Kumar Singh, Chun-Hao Chan, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 35
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2− breast tumor cells
Tarek M. Zikry, Samuel C. Wolff, Jolene S. Ranek, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 7
Open Access | Times Cited: 9
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
Agnieszka K. Witkiewicz, Vishnu Kumarasamy, Ioannis Sanidas, et al.
Trends in cancer (2022) Vol. 8, Iss. 9, pp. 711-725
Open Access | Times Cited: 30
Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment
Jie Liu, Min Cheng, Jiamei Xu, et al.
Immunological Investigations (2024) Vol. 53, Iss. 3, pp. 437-449
Closed Access | Times Cited: 6
The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
Mary Abdelmalak, Rajanbir Singh, Mohammed Anwer, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5388-5388
Open Access | Times Cited: 24
Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
Andreea-Iuliana Miron, Alexandra-Valentina Anghel, Andrei-Alexandru Barnonschi, et al.
Diagnostics (2023) Vol. 13, Iss. 11, pp. 1938-1938
Open Access | Times Cited: 16
Cancer takes many paths through G1/S
Erik S. Knudsen, Agnieszka K. Witkiewicz, Seth M. Rubin
Trends in Cell Biology (2023) Vol. 34, Iss. 8, pp. 636-645
Closed Access | Times Cited: 15
Cyclers’ kinases in cell division: from molecules to cancer therapy
Giacomo Milletti, Valeria Colicchia, Francesco Cecconi
Cell Death and Differentiation (2023) Vol. 30, Iss. 9, pp. 2035-2052
Open Access | Times Cited: 14
Herba Patriniae and its component Isovitexin show anti-colorectal cancer effects by inducing apoptosis and cell-cycle arrest via p53 activation
Jinxiao Li, Luorui Shang, Fangyuan Zhou, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115690-115690
Open Access | Times Cited: 12
Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment
Pratibha Pandey, Fahad Khan, Tarun Kumar Upadhyay, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2236-2236
Open Access | Times Cited: 11
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
Jin Sun Lee, Hannah Hackbart, Xiaojiang Cui, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11791-11791
Open Access | Times Cited: 11
Nanocomposite fibers based on cellulose acetate loaded with fullerene for cancer therapy: preparation, characterization and in-vitro evaluation
Gomaa El Fawal, Marwa M. Abu‐Serie, Safaa M. Ali, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Villosol reverses 5-FU resistance in colorectal cancer by inhibiting the CDKN2A gene regulated TP53-PI3K/Akt signaling axis
Han Chen, Jiao Deng, Tiewei Hou, et al.
Journal of Ethnopharmacology (2024) Vol. 325, pp. 117907-117907
Closed Access | Times Cited: 4
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
Thomas N. O’Connor, Emily Schultz, Jianxin Wang, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1749-1749
Open Access | Times Cited: 4
Tyrosol protects RPE cells from H2O2-induced oxidative damage in vitro and in vivo through activation of the Nrf2/HO-1 pathway
Longtai You, Wenwen Zhao, Li Xiao, et al.
European Journal of Pharmacology (2025), pp. 177316-177316
Closed Access
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
James J. Asciolla, Xuewei Wu, Christos Adamopoulos, et al.
Nature Cancer (2025) Vol. 6, Iss. 1, pp. 24-40
Closed Access
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future
Matthew Siskin, Minas P. Economides, David R. Wise
Cancers (2025) Vol. 17, Iss. 5, pp. 774-774
Open Access
Page 1 - Next Page

Scroll to top